企業概要
Embecta Corp. is a medical device enterprise dedicated to delivering solutions that enhance the health and wellbeing of individuals managing diabetes across the United States and global markets. The company operates within the healthcare sector, specifically specializing in the manufacturing and distribution of medical instruments and supplies such as pen needles, syringes, and safety injection devices. Embecta maintains a substantial operational scale with a total market capitalization of $525.28 million and an annual revenue base of $1.08 billion, supported by a workforce of 1,850 employees. These valuation and revenue figures indicate that Embecta holds a significant position in the specialized medical device industry, generating substantial gross revenue while maintaining a mid-cap profile that reflects its established presence in the diabetes care supply chain.
財務健全性
The company reported trailing twelve-month revenue of $1.08 billion, with a corresponding net income of $139.50 million and EBITDA reaching $366.70 million. The substantial gap between the $1.08 billion in revenue and the $139.50 million in net income highlights a cost structure where approximately 12.9% of total revenue is retained as profit, while the remaining portion covers the cost of goods sold, operating expenses, and interest obligations. Free cash flow stands at $188.91 million, which provides Embecta with considerable financial flexibility to fund research, development, or debt repayment without relying on external equity issuance. The gross margin is reported at 63.2%, indicating strong pricing power and efficient production costs relative to sales; the operating margin of 29.2% demonstrates effective control over administrative and selling expenses; and the profit margin of 12.9% reflects the final profitability after all corporate costs and interest. Regarding the balance sheet, Embecta holds $201.30 million in cash against total debt of $1.41 billion, resulting in a debt-to-equity ratio listed as N/A due to the negative price-to-book context, yet the absolute debt level is significant relative to cash reserves. The current ratio is 2.64, a metric that suggests the company possesses robust short-term liquidity, as it holds more than twice the value of current assets compared to its current liabilities. Return on equity is listed as N/A, while return on assets is 18.4%, a figure that reveals how efficiently management utilizes the company's asset base to generate earnings before interest and taxes.
バリュエーション評価
Embecta Corp. exhibits a trailing twelve-month P/E ratio of 3.76 and a forward P/E of 3.08. The difference between these two metrics implies that the market expects earnings growth in the future, as the forward multiple is lower than the trailing multiple, suggesting the anticipated earnings trajectory is viewed as positive by analysts. The price-to-book ratio is -0.86, which indicates a valuation significantly below the book value of the company's equity, a scenario often found in capital-intensive or restructuring sectors where market capitalization does not fully reflect asset value. Alternative valuation metrics include a price-to-sales ratio of 0.49 and an EV/EBITDA of 4.73, both of which suggest the stock is valued at a discount relative to its sales volume and earnings before interest, taxes, depreciation, and amortization. The 52-week trading range spans from a low of $8.47 to a high of $15.55, and the current price sits within this historical band, reflecting recent market volatility around the lower to mid-range of the annual cycle. The beta value is 1.10, which indicates that the stock price exhibits slightly higher volatility relative to the broader market, meaning Embecta tends to move more aggressively than the overall market index during periods of fluctuation.
Growth & Income
The revenue growth year-over-year is recorded at -0.3%, while the earnings growth year-over-year is listed as N/A. The absence of reported earnings growth data prevents a direct comparison of earnings versus revenue expansion rates, but the slight revenue contraction suggests a need for strategic focus on market share retention or price optimization. As a dividend payer, Embecta offers a dividend yield of 6.8% with a payout ratio of 25.4%, a combination that indicates the dividend is highly sustainable given that the company retains the vast majority of its earnings for operational reinvestment. The low payout ratio of 25.4% implies that Embecta retains significant earnings to fuel operations, pay down the $1.41 billion in debt, or invest in new product lines rather than distributing all profits to shareholders. Overall, the company presents a profile characterized by a high current yield supported by a conservative payout structure, despite a recent stagnation in top-line revenue growth.